MarketCapExport financials
Nephros (NEPH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Nephros Financial Ratios 2025-2009 | NEPH
Brief overview of Nephros's multiples and efficiency
Ratios are assessed across five available annual reports in the 2021–2025 interval.
Market valuation is represented by P/E 27.82x (median 51.32x), P/S 1.77x (median 1.62x), P/B 3.26x (median 2.7x). On average, multiples differ from their five-year medians by only +9.1%. Valuation is near its familiar historical range.
At the current P/E, inverse earnings yield is 3.6%, a useful bridge between price and business earnings.
Current measures of operating quality are ROE 11.7%, ROA 8.8%, ROCE 11.2%. Quality ratios send a mostly positive signal: resources are productive, with room for improvement.
PEG of 0.15x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
The cash conversion cycle decreased 222.6 days to 149.9 days, supporting working-capital efficiency.
Valuation takeaway
Nephros's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios Nephros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
27.8 | 310.1 | -14.3 | -1.5 | -11.7 | -15.3 | -20.8 | -10.7 | -30.8 | -7.7 | -3.9 | -2.3 | -1.7 | -4.8 | -3.2 | 51.3 | - |
P/S |
1.8 | 1.6 | 1.6 | 1.1 | 4.4 | 8.5 | 6.9 | 6.4 | 6.5 | 10.1 | 6.3 | 9.7 | 3.6 | 8.7 | 3.4 | - | - |
EPS |
0.1 | 0.0 | -0.1 | -0.7 | -0.4 | -0.5 | -0.5 | -0.5 | -0.0 | -0.1 | -0.1 | -0.3 | 0.1 | -0.6 | -0.8 | 1.9 | -6.3 |
EV (Enterprise Value) |
31.3 M | 21.8 M | 21.7 M | 9.4 M | 41.3 M | 67.5 M | 75.2 M | 35.5 M | 25.7 M | 25.1 M | 12.2 M | 24.7 M | 9.17 M | 19.8 M | 8.51 M | 199 M | -1 M |
EBITDA per Share |
0.12 | 0.01 | -0.13 | -0.4 | -0.31 | -0.477 | -0.394 | -0.417 | -0.341 | -0.489 | -0.83 | -0.927 | -1.78 | -2.55 | -2.31 | -0.84 | - |
EV/EBITDA |
24.3 | 154.7 | -15.8 | -2.3 | -8.7 | -15.2 | -23.1 | -11.8 | -12.1 | -9.0 | -3.4 | -6.4 | -2.3 | -4.9 | -2.7 | -113.0 | - |
PEG |
0.15 | -9.69 | 1.24 | -0.24 | 2.14 | 0.38 | -1.25 | 0.05 | -0.46 | -0.23 | -0.06 | 0.08 | -0.1 | 0.65 | -0.05 | - | - |
P/B |
3.3 | 2.7 | 2.7 | 1.2 | 3.1 | 5.8 | 15.2 | 9.6 | 12.8 | 35.0 | 4.6 | -3.0 | -10.2 | -26.4 | 5.4 | 125.2 | - |
P/CF |
20.2 | -46.6 | 27.3 | -3.4 | -32.0 | -10.2 | -31.1 | -9.9 | -323.1 | -10.8 | -3.2 | -6.8 | -1.7 | -7.1 | -5.9 | - | - |
ROE % |
11.70 | 0.86 | -18.84 | -127.07 | -33.07 | -38.06 | -73.16 | -89.57 | -41.49 | -454.57 | -115.92 | 129.75 | 606.23 | 548.24 | -166.08 | 2874.07 | -617.06 |
ROA % |
8.75 | 0.66 | -13.28 | -64.61 | -21.91 | -25.75 | -29.41 | -32.22 | -16.24 | -113.22 | -77.78 | -218.79 | -128.00 | -92.46 | -59.09 | 244.03 | - |
ROCE % |
11.23 | 0.07 | -19.06 | -77.52 | -27.81 | -26.21 | -34.29 | -38.16 | -71.53 | -160.91 | -113.62 | -125.78 | 543.77 | -2975.89 | -162.56 | -1399.26 | - |
Current Ratio |
4.0 | 4.3 | 3.4 | 5.2 | 6.1 | 11.4 | 3.4 | 3.1 | 2.0 | 1.4 | 2.6 | 1.4 | 0.3 | 0.4 | 1.2 | - | - |
DSO |
40.7 | 42.2 | 35.7 | 53.6 | 53.7 | 58.2 | 36.9 | 93.2 | 80.1 | 61.0 | 74.5 | 23.0 | 25.6 | 188.9 | 192.9 | - | - |
DIO |
148.9 | 170.6 | 175.9 | 265.0 | 388.8 | 530.7 | 220.0 | 273.9 | 162.2 | 170.4 | 244.0 | 123.7 | 65.8 | 154.5 | 67.0 | - | - |
DPO |
39.8 | 51.1 | 50.5 | 72.2 | 70.0 | 42.3 | 82.4 | 122.8 | 209.8 | 208.1 | 269.2 | 555.1 | 436.1 | 1182.7 | 77.0 | - | - |
Operating Cycle |
189.7 | 212.8 | 211.6 | 318.6 | 442.5 | 588.8 | 256.9 | 367.1 | 242.3 | 231.4 | 318.6 | 146.6 | 91.4 | 343.4 | 259.9 | - | - |
Cash Conversion Cycle |
149.9 | 161.8 | 161.1 | 246.4 | 372.5 | 546.5 | 174.6 | 244.2 | 32.5 | 23.3 | 49.4 | -408.5 | -344.7 | -839.3 | 182.9 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Nephros
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.02 | 0.01 | - | 0.03 | 0.02 | 0.05 | - | 0.02 | -0.03 | -0.02 | - | -0.02 | -0.04 | -0.03 | - | -0.31 | -0.12 | -0.2 | - | -0.12 | -0.12 | -0.06 | - | -0.12 | -0.19 | -0.13 | - | -0.1 | -0.14 | -0.2 | - | -0.08 | -0.1 | -0.03 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.02 | -0.02 | - | -0.02 | -0.06 | 0.01 | - | 0.11 | -0.21 | -0.19 | - | -0.14 | -0.1 | 0.13 | - | -0.07 | -0.07 | -0.05 | - | -0.04 | -0.06 | -0.18 |
EBITDA per Share |
0.02 | 0.01 | - | 0.03 | 0.03 | 0.06 | - | 0.02 | -0.03 | -0.02 | - | -0.01 | -0.04 | -0.02 | - | -0.12 | -0.07 | -0.15 | - | -0.07 | -0.11 | -0.1 | - | -0.1 | -0.17 | -0.11 | - | -0.08 | -0.11 | -0.18 | - | -0.07 | -0.09 | -0.02 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.02 | -0.02 | - | -0.03 | -0.02 | -0.02 | - | -0.02 | -0.02 | -0.03 | - | -0.03 | -0.04 | -0.08 | - | -0.07 | -0.07 | -0.05 | - | -0.04 | -0.06 | -0.06 |
ROE % |
13.64 | 13.15 | 11.84 | 14.08 | 7.07 | 2.53 | -3.47 | -5.58 | -12.83 | -12.62 | -10.55 | -43.47 | -50.47 | -60.15 | -56.71 | -64.68 | -39.27 | -33.62 | -18.94 | -27.02 | -32.28 | -33.54 | -30.08 | -46.00 | -58.07 | -73.69 | -64.92 | -79.82 | -81.86 | -99.34 | -70.48 | -102.89 | -128.30 | -145.21 | -107.59 | -213.44 | -306.21 | -391.24 | -356.37 | -378.18 | -340.46 | -206.16 | -80.82 | -128.75 | -12.96 | 116.97 | 107.85 | 502.60 | 760.21 | 418.03 | 356.23 | 499.59 | 231.56 | 115.50 | 363.70 | 334.63 | 148.91 | -27.57 | -121.18 | -29.06 | -42.36 | -49.75 |
ROA % |
9.59 | 10.23 | 9.22 | 10.98 | 5.83 | 2.42 | -2.32 | -3.99 | -9.92 | -10.12 | -8.64 | -36.46 | -42.40 | -50.90 | -48.10 | -54.95 | -33.39 | -28.78 | -16.11 | -21.58 | -23.67 | -23.35 | -20.35 | -26.75 | -29.38 | -32.03 | -26.10 | -31.46 | -31.52 | -36.96 | -25.36 | -38.04 | -48.45 | -55.64 | -42.10 | -68.47 | -86.96 | -102.41 | -88.76 | -103.40 | -122.75 | -85.45 | -54.23 | 26.59 | -117.25 | -175.74 | -181.86 | -265.21 | -390.31 | -179.43 | -75.22 | -99.39 | -37.42 | -8.93 | -61.34 | -71.68 | -62.57 | -58.90 | -43.11 | -10.34 | -15.07 | -17.70 |
ROCE % |
9.52 | 12.72 | 11.81 | 14.33 | 7.20 | 2.17 | -3.92 | -6.28 | -13.82 | -13.27 | -10.82 | -24.19 | -28.36 | -34.88 | -31.44 | -36.67 | -30.75 | -30.78 | -19.23 | -26.68 | -34.21 | -34.95 | -28.40 | -43.26 | -54.39 | -69.46 | -61.26 | -74.72 | -77.04 | -88.04 | -60.22 | -86.78 | -109.22 | -123.06 | -93.49 | -188.99 | -284.91 | -369.86 | -338.83 | -379.63 | -306.43 | -214.20 | -93.36 | -81.37 | -29.37 | 2.82 | 33.08 | 132.75 | 223.71 | 377.76 | 367.87 | 511.23 | 548.03 | 538.52 | 373.28 | 343.37 | 157.92 | -24.01 | -117.45 | -29.91 | -42.08 | -45.46 |
Current Ratio |
4.0 | 4.5 | 4.3 | 4.1 | 4.6 | 4.7 | 4.3 | 4.7 | 3.5 | 3.5 | 3.4 | 4.8 | 6.0 | 5.4 | 5.2 | 6.5 | 6.0 | 7.3 | 6.1 | 7.2 | 6.0 | 7.5 | 6.3 | 6.3 | 6.3 | 6.3 | 3.0 | 3.0 | 3.0 | 3.0 | 2.8 | 2.8 | 2.8 | 2.8 | 1.6 | 1.6 | 1.6 | 1.6 | 1.3 | 1.3 | 1.3 | 1.3 | 3.0 | 3.0 | 3.0 | 3.0 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.8 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 0.9 | 1.6 | 1.6 | 1.6 | 1.6 |
DSO |
61.3 | 46.4 | - | 45.0 | 48.7 | 41.7 | - | 46.3 | 47.6 | 39.0 | - | 36.8 | 45.5 | 40.1 | - | 66.3 | 54.8 | 62.0 | - | 52.0 | 62.4 | 51.4 | - | 58.7 | 78.9 | 43.5 | - | 30.8 | 41.3 | 62.0 | - | 76.8 | 97.0 | 106.0 | - | 83.3 | 88.8 | 76.1 | - | 74.5 | 69.6 | 60.7 | - | 113.2 | 63.9 | 42.5 | - | 20.4 | 22.8 | 22.4 | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
192.5 | 128.2 | - | 122.8 | 117.7 | 121.0 | - | 196.7 | 190.1 | 179.4 | - | 129.5 | 139.2 | 158.2 | - | 225.8 | 293.0 | 377.1 | - | 364.7 | 449.6 | 396.4 | - | 540.2 | 709.7 | 345.8 | - | 183.2 | 248.2 | 261.9 | - | 220.3 | 317.3 | 223.5 | - | 160.2 | 179.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
66.8 | 43.4 | - | 38.7 | 33.4 | 31.9 | - | 51.9 | 77.4 | 67.9 | - | 32.6 | 31.8 | 42.0 | - | 60.7 | 72.4 | 92.0 | - | 65.2 | 73.4 | 36.5 | - | 43.1 | 56.6 | 60.8 | - | 68.6 | 92.9 | 106.2 | - | 98.8 | 142.3 | 150.4 | - | 207.2 | 232.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 167.8 | 166.4 | 162.7 | - | 243.0 | 237.7 | 218.4 | - | 166.3 | 184.8 | 198.3 | - | 292.2 | 347.7 | 439.1 | - | 416.7 | 512.0 | 447.8 | - | 598.9 | 788.6 | 389.2 | - | 214.0 | 289.5 | 323.9 | - | 297.2 | 414.3 | 329.5 | - | 243.4 | 268.6 | 76.1 | - | 74.5 | 69.6 | 60.7 | - | 113.2 | 63.9 | 42.5 | - | 20.4 | 22.8 | 22.4 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | 129.1 | 133.0 | 130.8 | - | 191.1 | 160.3 | 150.5 | - | 133.7 | 153.0 | 156.4 | - | 231.5 | 275.4 | 347.1 | - | 351.5 | 438.6 | 411.4 | - | 555.8 | 732.0 | 328.5 | - | 145.4 | 196.6 | 217.7 | - | 198.4 | 272.0 | 179.1 | - | 36.2 | 36.0 | 76.1 | - | 74.5 | 69.6 | 60.7 | - | 113.2 | 63.9 | 42.5 | - | 20.4 | 22.8 | 22.4 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Nephros, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
electroCore
ECOR
|
$ 11.42 | 2.46 % | $ 96.9 K | USA |
 |
Alcon
ALC
|
$ 65.39 | 0.02 % | $ 32.3 B |  Schweiz |
 |
Glaukos Corporation
GKOS
|
$ 153.49 | 0.19 % | $ 8.78 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 106.82 | 0.01 % | $ 5.04 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.05 | 1.64 % | $ 357 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 12.7 | 2.26 % | $ 262 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 111.75 | 1.1 % | $ 3.58 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 398.3 | 0.06 % | $ 142 B | USA |
 |
AngioDynamics
ANGO
|
$ 15.51 | 0.26 % | $ 644 M | USA |
 |
Repro Med Systems
KRMD
|
$ 3.27 | 2.42 % | $ 151 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 80.58 | 0.12 % | $ 1.82 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.31 | 0.36 % | $ 60 M |  Israel |
 |
Merit Medical Systems
MMSI
|
$ 87.07 | 0.1 % | $ 5.15 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.82 | 0.41 % | $ 4 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.99 | 8.13 % | $ 293 M | USA |
 |
Pro-Dex
PDEX
|
$ 71.94 | 0.12 % | $ 232 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.98 | 0.25 % | $ 3.5 B | USA |
 |
Repligen Corporation
RGEN
|
$ 184.53 | 0.81 % | $ 10.4 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | 0.36 % | $ 21 M | USA |
 |
AtriCure
ATRC
|
$ 59.96 | 1.91 % | $ 2.86 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.8 | 1.62 % | $ 981 M | USA |
 |
STERIS plc
STE
|
$ 209.98 | 0.61 % | $ 20.6 B | USA |
 |
Stereotaxis
STXS
|
$ 1.32 | 2.94 % | $ 120 M | USA |
 |
BioLife Solutions
BLFS
|
$ 37.74 | 0.37 % | $ 1.8 B | USA |
 |
Baxter International
BAX
|
$ 23.49 | 0.17 % | $ 12.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 75.01 | 2.93 % | $ 243 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 375.87 | 1.29 % | $ 27.2 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 182.52 | 0.01 % | $ 52.5 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.78 | 0.05 % | $ 1.95 B | USA |
 |
The Cooper Companies
COO
|
$ 56.07 | 1.41 % | $ 11.2 B | USA |
 |
ICU Medical
ICUI
|
$ 163.32 | 1.45 % | $ 4.02 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.42 | 4.73 % | $ 34.5 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 121.75 | 0.08 % | $ 5.43 B | USA |
 |
ResMed
RMD
|
$ 222.3 | 0.15 % | $ 32.3 B | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |